Provided by Tiger Trade Technology Pte. Ltd.

VistaGen Therapeutics

0.3078
+0.00983.29%
Post-market: 0.2950-0.0128-4.16%19:55 EDT
Volume:2.43M
Turnover:739.77K
Market Cap:13.66M
PE:-0.19
High:0.3180
Open:0.2896
Low:0.2840
Close:0.2980
52wk High:5.14
52wk Low:0.1980
Shares:44.38M
Float Shares:41.42M
Volume Ratio:0.02
T/O Rate:5.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6559
EPS(LYR):-1.8303
ROE:-166.46%
ROA:-83.21%
PB:0.56
PE(LYR):-0.17

Loading ...

SRX Global says adds investment in Onconetix

TIPRANKS
·
Sep 25

SRX Global Adds Minority Equity Stake in Onconetix

Reuters
·
Sep 25

Srx Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: Onco)

THOMSON REUTERS
·
Sep 25

VistaGen Reports Exploratory Trial Data Show Fasedienol Eases Anxiety in Very Severe Social Anxiety Subgroup

Reuters
·
Sep 24

Analysts Have Conflicting Sentiments on These Healthcare Companies: Codexis (CDXS) and VistaGen Therapeutics (VTGN)

TIPRANKS
·
Sep 23

Vistagen Therapeutics, - Fasedienol Nasal Spray Well-Tolerated with no New Drug-Related Safety Findings After 12 Months

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - no Serious Adverse Events Related to Fasedienol Reported

THOMSON REUTERS
·
Sep 22

Vistagen Announces Preliminary Positive Data from Open-Label Extension Portion of Palisade-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - Discontinuation Rate Due to Adverse Events was 1.6%, None Attributed to Fasedienol

THOMSON REUTERS
·
Sep 22

Vistagen Therapeutics, - Preparing to Meet with FDA This Quarter for Proposed New Phase 3 Trial

THOMSON REUTERS
·
Sep 22

VistaGen Therapeutics Holds Annual Shareholder Meeting

Reuters
·
Sep 11

VistaGen Reports Phase 3 Fasedienol Shows Positive Efficacy Signal in Severe Social Anxiety Subgroup Analysis

Reuters
·
Sep 10

Inflammation Drug Developer HCW Biologics' Q2 Net Loss Widens

Reuters
·
Aug 15

VistaGen Therapeutics Q1 EPS $(0.30) Beats $(0.36) Estimate, Sales $1.476M Beat $250.000K Estimate

Benzinga Earnings
·
Aug 14

VistaGen Q1 Revenue Rises on Licensing Agreement Expiration

Reuters
·
Aug 14

VistaGen Q1 EPS USD -0.3

Reuters
·
Aug 14

Vistagen Q1 Net Income USD -13.03 Million

THOMSON REUTERS
·
Aug 14

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update

THOMSON REUTERS
·
Aug 14

Analysts’ Opinions Are Mixed on These Healthcare Stocks: VistaGen Therapeutics (VTGN), Iovance Biotherapeutics (IOVA) and Aurinia Pharmaceuticals (AUPH)

TIPRANKS
·
Aug 06

Vistagen announces topline results from fasedienol repeat dose study

TIPRANKS
·
Aug 06